A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Certain cancers and Parkinson's disease are especially difficult to treat ... initiative with a leading pharmaceutical ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of ... The study was backed by the Aufzien ...

(WDRB) -- Norton Healthcare's Neuroscience Institute will soon begin offering a non-invasive procedure to reduce tremors in Parkinson's patients ... s disease, according to a news release.